Natrecor

Natrecor is a brand name of nesiritide, approved by the FDA in the following formulation(s):

NATRECOR (nesiritide recombinant - for solution; intravenous)

• 
  Manufacturer: SCIOS
  
  Approval date: August 10, 2001
  
  Strength(s): 1.5MG/VIAL ^[RLD]

Has a generic version of Natrecor been approved?

No. There is currently no therapeutically equivalent version of Natrecor available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Natrecor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Recombinant techniques for production of novel natriuretic and vasodilator peptides
  Patent 5,114,923
  Issued: May 19, 1992
  Inventor(s): Seilhamer; Jeffrey J. & Lewicki; John A. & Scarborough; Robert M. & Porter; J. Gordon
  Assignee(s): California Biotechnology Inc.
  The cDNA sequence encoding porcine brain natriuretic peptide and related genes encoding canine and human peptides with natriuretic activity are disclosed. The gene is shown to make accessible the DNAs encoding analogous natriuretic peptides in other vertebrate species. The genes encoding these NPs can be used to effect modifications of the sequence to produce alternate forms of the NPs and to provide practical amounts of these proteins. The NPs of the invention can also be synthesized chemically. The invention peptides have the formula: ##STR1## wherein R.sup.1 is selected from the group consisting of: ##STR2## or a 10- to 109-amino acid sequence shown as the native upstream sequence for porcine, canine or human NP in FIG. 6, or a composite thereof; R.sup.2 is (OH), NH.sub.2, or NR'R" wherein R' and R" are independently lower alkyl (1-4C) or is ##STR3## or the amides (NH.sub.2 or NR'R") thereof, with the proviso that if formula (1) is EQU R.sup.1 -Cys-Phe-Gly-Arg-Arg-Leu-Asp-Arg- Ile-Gly-Ser-Leu-Ser-Gly-Leu-Gly-Cys-R.sup.2 and R.sup.1 is Asp-Ser-Gly-, R.sup.2 cannot be Asn-Val-Leu-Arg-Arg-Tyr. The peptides of the invention can be formulated into pharmaceutical compositions and used to treat conditions associated with high extracellular fluid levels, especially congestive heart failure.
  
  Patent expiration dates:
  
  
  • May 19, 2014
    
    ✓ 
    Patent use: METHOD TO INDUCE NATRIURESIS, DIURESIS AND/OR VASODILATION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

See also...

• Natrecor Consumer Information (Drugs.com)
• Natrecor Consumer Information (Wolters Kluwer)
• Natrecor Consumer Information (Cerner Multum)
• Natrecor Advanced Consumer Information (Micromedex)
• Natrecor AHFS DI Monographs (ASHP)
• Nesiritide Consumer Information (Wolters Kluwer)
• Nesiritide Consumer Information (Cerner Multum)
• Nesiritide Intravenous Advanced Consumer Information (Micromedex)
• Nesiritide AHFS DI Monographs (ASHP)